Implementing evidence-driven individualized treatment plans within Morquio A Syndrome

Area of Science:

• Genetics and rare diseases
• Lysosomal storage disorders
• Biochemical genetics

Background:

• Morquio A Syndrome (mucopolysaccharidosis IVA) is an inherited lysosomal storage disorder caused by GALNS enzyme deficiency.
• Deficient N-acetylgalactosamine-6-sulfate sulfatase (GALNS) activity leads to glycosaminoglycan (GAG) accumulation.
• This accumulation causes progressive multisystem dysfunction, affecting skeletal, respiratory, and cardiac systems.

Purpose of the Study:

• To provide updated information and guidelines on the diagnosis and management of Morquio A Syndrome.
• To review recent advances in enzyme replacement therapies (ERTs) for Morquio A Syndrome.
• To offer practical solutions for clinicians regarding newer therapeutics and care models.

Main Methods:

• Review of a live satellite symposium from the 2015 ACMG Annual Clinical Genetics Meeting.
• Compilation of updated scientific information and clinical trial data on Morquio A Syndrome.
• Focus on early diagnosis, intervention, and management strategies.

Main Results:

• Morquio A Syndrome presents with significant clinical heterogeneity due to allelic heterogeneity.
• Enzyme replacement therapies offer pharmacological intervention opportunities to improve quality of life.
• Management strategies for cardiopulmonary comorbidities are crucial for patient care.

Conclusions:

• Early and accurate diagnosis of Morquio A Syndrome is essential for timely intervention.
• Advances in ERTs provide new avenues for improving patient outcomes and quality of life.
• A comprehensive clinical care model addressing multisystemic manifestations is recommended.